Arctic Bioscience AS (FRA:9TD) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:9TD Arctic Bioscience AS FRA:9TD
59 GF Score
Price €0.24
GF Value €1.02
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Arctic Bioscience AS Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:9TD
59GF Score
Arctic Bioscience AS FRA:9TD
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Arctic Bioscience AS (FRA:9TD) Overvalued in 2026?

Based on GuruFocus' analysis, Arctic Bioscience AS stock appears to be undervalued. The current stock price of €0.24 is trading 76.2% below its estimated GF Value™ of €1.02. GuruFocus considers Arctic Bioscience AS to be Possible Value Trap.

Key valuation signals for FRA:9TD:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €1.02 vs. price of €0.24 (76.2% below fair value)
  • GF Score™: 59/100 with 6 warning signs

No single metric tells the full story. See the FRA:9TD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arctic Bioscience AS Business Description

Other Exchanges ABS:Norway
Address Industrivegen 42, Orsta, NOR, 6155
Arctic Bioscience AS is a clinical-stage biotechnology company working to develop drug candidates within the areas of autoimmune and inflammatory diseases. It is developing pharmaceutical and commercializing nutraceutical products based on bioactive marine compounds, including lipids essential to maintaining cell membranes. The company's proprietary extraction technology is used to extract membrane fats from marine raw materials, such as herring roe and algae. Geographically, the company operates in Norway, the Americas, Europe, and APAC, with the majority of the revenue derived from the Americas.
59GF Score

Get the complete analysis for FRA:9TD

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.24
Price
€1.02
GF Value